| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
266,801 |
367,551 |
1,208,027 |
1,426,093 |
| Total Sell Value |
$17,625,431 |
$23,079,873 |
$71,079,228 |
$79,452,297 |
| Total People Sold |
8 |
8 |
11 |
11 |
| Total Sell Transactions |
22 |
34 |
81 |
84 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-17 |
4 |
AS |
$62.09 |
$362,357 |
I/I |
(5,836) |
745,475 |
|
- |
|
| Tannenbaum Renee P |
Director |
– • – |
2024-05-16 |
4 |
S |
$63.87 |
$127,740 |
D/D |
(2,000) |
18,211 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-16 |
4 |
AS |
$63.84 |
$1,050,743 |
I/I |
(16,459) |
751,311 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-15 |
4 |
AS |
$65.86 |
$978,021 |
I/I |
(14,850) |
767,770 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-05-14 |
4 |
S |
$66.10 |
$1,101,821 |
D/D |
(16,669) |
377,505 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-05-13 |
4 |
AS |
$67.69 |
$16,923 |
D/D |
(250) |
59,481 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-05-01 |
4 |
AS |
$66.62 |
$1,332,400 |
I/I |
(20,000) |
233,226 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-19 |
4 |
AS |
$65.17 |
$1,095,443 |
I/I |
(16,809) |
782,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-18 |
4 |
AS |
$64.98 |
$677,287 |
I/I |
(10,423) |
799,429 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-17 |
4 |
AS |
$65.40 |
$622,608 |
I/I |
(9,520) |
809,852 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-16 |
4 |
AS |
$66.20 |
$386,211 |
I/I |
(5,834) |
819,372 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-15 |
4 |
AS |
$66.33 |
$491,771 |
I/I |
(7,414) |
825,206 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-04-12 |
4 |
AS |
$67.79 |
$16,948 |
D/D |
(250) |
59,731 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-04-10 |
4 |
D |
$66.96 |
$187,421 |
D/D |
(2,799) |
116,006 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-04-10 |
4 |
D |
$66.96 |
$303,597 |
D/D |
(4,534) |
166,968 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-04-01 |
4 |
AS |
$67.25 |
$1,345,000 |
I/I |
(20,000) |
253,226 |
|
- |
|
| Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS |
• – – |
2024-03-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,036 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-03-23 |
4 |
D |
$69.58 |
$1,214,519 |
D/D |
(17,455) |
394,174 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-03-23 |
4 |
D |
$69.58 |
$432,092 |
D/D |
(6,210) |
171,502 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-03-23 |
4 |
D |
$69.58 |
$254,176 |
D/D |
(3,653) |
118,805 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-03-13 |
4 |
AS |
$66.54 |
$16,635 |
D/D |
(250) |
59,981 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-03-11 |
4 |
AS |
$65.81 |
$1,316,200 |
I/I |
(20,000) |
273,226 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-03-11 |
4 |
S |
$65.55 |
$510,438 |
D/D |
(7,787) |
177,712 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-08 |
4 |
AS |
$67.17 |
$671,700 |
I/I |
(10,000) |
832,620 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-03-08 |
4 |
S |
$67.13 |
$1,093,682 |
D/D |
(16,292) |
411,629 |
|
- |
|
711 Records found
|
|
Page 1 of 29 |
|
|
0.14 (0.21%) 
